Indiviorplc (IZQVF) 3.5600 $IZQVF
Stock In Focus: Indivior
Stockopedia - Seeking Alpha - Wed Jul 01, 7:47AM CDT
How can a company that's only been listed for six months be the highest-ranked stock on Stockopedia , with a StockRank of 100? It's a question I've been asking myself as I've watched shares of Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) climb by 57%...
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 8.64 (+0.15), INSY: 37.53 (+0.49), HRTX: 32.49 (+2.33), PFE: 34.36 (+0.50), ALKS: 64.22 (+1.88), ACUR: 0.92 (+0.03), OMER: 17.33 (+0.29)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 8.64 (+0.15), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), ACUR: 0.92 (+0.03), JNJ: 99.53 (+1.13), INSY: 37.53 (+0.49), TRGT: 2.68 (-0.06), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), ABBV: 69.23 (+1.26), ARNA: 4.29 (+0.04)
Indivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia
PR Newswire - Tue May 05, 6:00AM CDT
Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the 8-week treatment period using change from baseline to end of treatment.
Indivior PLC: An Undervalued Spin-Off With Room For Growth
Rupert Hargreaves - at Seeking Alpha - Fri Jan 30, 3:08PM CST
Stock In Focus: Indivior
Stockopedia - Seeking Alpha - Wed Jul 01, 7:47AM CDT
How can a company that's only been listed for six months be the highest-ranked stock on Stockopedia , with a StockRank of 100? It's a question I've been asking myself as I've watched shares of Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) climb by 57%...
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 8.64 (+0.15), INSY: 37.53 (+0.49), HRTX: 32.49 (+2.33), PFE: 34.36 (+0.50), ALKS: 64.22 (+1.88), ACUR: 0.92 (+0.03), OMER: 17.33 (+0.29)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 8.64 (+0.15), PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), ACUR: 0.92 (+0.03), JNJ: 99.53 (+1.13), INSY: 37.53 (+0.49), TRGT: 2.68 (-0.06), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), ABBV: 69.23 (+1.26), ARNA: 4.29 (+0.04)
Indivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia
PR Newswire - Tue May 05, 6:00AM CDT
Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the 8-week treatment period using change from baseline to end of treatment.
Indivior PLC: An Undervalued Spin-Off With Room For Growth
Rupert Hargreaves - at Seeking Alpha - Fri Jan 30, 3:08PM CST
